TrialClinical cancer research : an official journal of the American Association for Cancer Research2008

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.

Carlos L Arteaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.